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Abstract: Melittin, the main peptide present in bee venom, has been proposed as having potential for
anticancer therapy; the addition of melittin to cisplatin, a first line treatment for ovarian cancer,
may increase the therapeutic response in cancer treatment via synergy, resulting in improved
tolerability, reduced relapse, and decreased drug resistance. Thus, this study was designed to
compare the metabolomic effects of melittin in combination with cisplatin in cisplatin-sensitive
(A2780) and resistant (A2780CR) ovarian cancer cells. Liquid chromatography (LC) coupled with
mass spectrometry (MS) was applied to identify metabolic changes in A2780 (combination treatment
5 µg/mL melittin + 2 µg/mL cisplatin) and A2780CR (combination treatment 2 µg/mL melittin
+ 10 µg/mL cisplatin) cells. Principal components analysis (PCA) and orthogonal partial least squares
discriminant analysis (OPLS-DA) multivariate data analysis models were produced using SIMCA-P
software. All models displayed good separation between experimental groups and high-quality
goodness of fit (R2) and goodness of prediction (Q2), respectively. The combination treatment
induced significant changes in both cell lines involving reduction in the levels of metabolites in the
tricarboxylic acid (TCA) cycle, oxidative phosphorylation, purine and pyrimidine metabolism, and
the arginine/proline pathway. The combination of melittin with cisplatin that targets these pathways
had a synergistic effect. The melittin-cisplatin combination had a stronger effect on the A2780 cell
line in comparison with the A2780CR cell line. The metabolic effects of melittin and cisplatin in
combination were very different from those of each agent alone.
Keywords: melittin; cisplatin; synergy; sensitive and resistant ovarian cancer cells; metabolomics
1. Introduction
Combination therapy has long been studied in the treatment of cancer, including ovarian cancer [1].
It is a logical approach, focusing on increasing the response and tolerability to treatment, while also
decreasing resistance [2]. Unfortunately, it can be difficult to assess whether a particular combination
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will behave in a synergistic, additive, or antagonist fashion when used on a particular cancer patient.
The only known way of determining their effectiveness is to identify specific measures, such as
response rate, survival, or time to progression, and assess if or whether the new combination is
able to achieve a significant improvement [2]. Combination therapy is essentially cooperative: each
agent involved should have non-overlapping toxicities, different mechanisms of action with minimal
cross-resistance, and individually proven in treatment by itself [2].
Several cancers, including ovarian cancer, have demonstrated resistance or reduced sensitivity to
cisplatin treatment, leading to decreased time to disease progression, increased likelihood of relapse,
and reduced efficacy upon re-treatment during relapse [3,4]; cisplatin itself causes significant health
problems, such as nephrotoxicity [5]. Ideally, cisplatin in combination with a drug that diminishes its
negative effects while enhancing the therapeutic effects would decrease resistance or relapse while
mitigating its negative effects. For example, cisplatin (or another platinum agent) in combination
with taxanes (e.g., paclitaxel) is now regarded as standard chemotherapy in ovarian cancer, where the
taxane enhances the tumour’s radiosensitivity. Cisplatin and the adenovirus OBP-301 have also been
shown to work synergistically [1].
Cisplatin shares cytotoxic synergywith bee venom [1]. Bee venommakes sense as a complement to
cisplatin: it has protective effects in many areas of the body such as the blood and nerves [6]; it is able to
inhibit cell growth in tumours [7]; and has even been examined and used in complementary treatments
that are necessitated by the effects of chemotherapy, such as allodynia [8] and neuropathy [9]. Cisplatin
in combination with bee venom has been successfully used against human cervical and laryngeal
carcinoma cells, including their drug-resistant sublines [10], and human glioblastoma [11]. Several
studies have found that phospholipase A2, another component of bee venom, not only mitigates
the negative impact of cisplatin on kidneys [12], but also boosts regulatory T cell (Treg) numbers in
the spleen and enhances Treg traffic to the kidneys following cisplatin exposure. This is important,
as Tregs play a significant role in many mechanisms, including inflammation and autoimmunity
suppression [4,12,13]. A significant bonus in this dynamic is that bee venom has no negative impact
on the anti-cancer properties of the cisplatin [4], meaning it in no way diminishes the effect of the
cisplatin treatment. This is critical; a combinatory agent which diminishes any positive effects of the
primary treatment undermines its effectiveness overall. The effects that cisplatin and bee venom have
together on ovarian cancer cells emerge from the synergistic relationship between the two agents [14].
Alizadehnohi et al. report that separately and together, the two agents induce apoptosis in human
ovarian cancer cells; bee venom appears to enhance the cytotoxic impact of cisplatin [14]. It also
appears that melittin provokes responses in cisplatin-sensitive cells which lead to decreasing levels of
amino acids, which in turn affect the energy metabolism of the tumour [15].
In order to understand these effects and the metabolic changes that the cisplatin-melittin
combination has on ovarian cancer cells, metabolomic investigations can be undertaken. Metabolomics
in the context of oncology usefully focuses on diagnosis and prognosis, as well as on evaluating
the effectiveness of therapy [16,17]. For instance, one study employed nuclear magnetic resonance
(1H-NMR) spectroscopy and was able to accurately separate serum metabolite profiles of three groups
of patients: namely women with ovarian cancer, normal premenopausal women, and women with a
benign ovarian disease [18]. In addition, LC-MS in combination with BiologMicroarray assays revealed
that treatment of cisplatin-resistant and sensitive ovarian cancer cells with melittin distinctively altered
their lipid profiles and their ability tometabolise certain carbon energy sources, [15]. NMR spectroscopy
has also been used to produce and examine metabolic profiles in other cancers such as hepatocellular
carcinoma [19].
In essence, the effects of the cytotoxic mechanisms of both cisplatin and melittin, together and
separately, cause changes in cells which can be identified and measured through metabolomic analysis.
The current study aimed to examine the metabolic effects of melittin in combination with cisplatin on
A2780 and A2780CR human ovarian cancer cell lines using a LC-MS based metabolomics approach
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employing a ZIC-pHILIC column. Multivariate data analysis was performed based on PCA and
OPLS-DA models constructed using the SIMCA-P software.
2. Results
2.1. The Cytotoxicity of Melittin in Combination with Cisplatin
The viabilities of the cisplatin-sensitive and cisplatin-resistant ovarian cancer cells (OCCs) (A2780
and A2780CR, respectively) treated with melittin or cisplatin were compared. Both single treatments
exerted a concentration-dependent cytotoxic effect on A2780 and A2780CR cells (Figure 1). The
cisplatin mediated growth inhibition of the sensitive cell line (A2780) was significantly greater than
that of the melittin over the concentration range of 1 to 8 µg/mL (Figure 1A; p < 0.05). However, the
A2780CR cells, as expected, were more resistant to cisplatin than the A2780 cells (Figure 1B). The 24 h
half maximal inhibitory concentrations (IC50) of cisplatin in A2780CR and A2780 cells were 10.8 and
4.9 µg/mL, respectively. Melittin exhibited toxicity against both A2780CR and A2780 cells, with IC50
values of 4.5 and 6.8 µg/mL, respectively [15] (Figures S1 and S2). The cytotoxicity of melittin in
combination with cisplatin against A2780 and A2780CR cells was studied by using an Alamar® Blue
assay [15]. The A2780 and A2780CR cells were treated for 24 h at various concentrations of melittin in
combination with cisplatin. The percentage of surviving cells decreased in a dose-dependent manner
in both cell lines. The cytotoxic effects of melittin in combination with cisplatin on A2780 and A2780CR
cell lines are shown in Figures 2A and 3A, respectively.
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Figure 1. Examination of cell viability after treatment with either cisplatin or melittin alone with
various concentrations on (A) A2780 and (B) A2780CR cell lines. * Significantly different from zero.
concentration at <0.05; *** Significant at <0.001.
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2.2. The Combination Index (CI)
In order to qualitatively evaluate whether the combination of melittin with cisplatin might cause
synergistic cytotoxic effects, the value of CI, a commonly used evaluation index, was calculated. It has
been proposed that CI values be interpreted as follows: <0.1 very strong synergism, 0.1–0.3 strong
synergism, 0.3–0.7 synergism, 0.7–0.9 moderate to slight synergism, 0.9–1.1 nearly additive, 1.1–1.45
slight to moderate antagonism, 1.45–3.3 antagonism, and >3.3 strong to very strong antagonism [20].
ΐ
ΐ
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ΐ ΐ
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Figure 2. Effects of melittin in combination with cisplatin on (A) cell viability of A2780 cell lines and
(B) combination index. (A) The A2780 cells were treated with various concentrations of the melittin
+ cisplatin combination for 24 h. Bar graphs represent mean ± SD values. (B) Combination index
(CI) analysis was generated using the method of Chou and Talalay [21,22] to determine the extent of
synergy, if any, for the melittin + cisplatin combination on A2780 cell lines.
The CI analyses showed that synergistic cytotoxic activity on A2780 cells occurred with the
melittin + cisplatin combinations at concentrations of 5 + 2 (CI = 0.647) and 6 + 2 (CI = 0.512) µg/mL,
and with the cisplatin+melittin combinations at concentrations of 4 + 3 (CI = 0.789) and 5 + 3
(CI = 0.711) µg/mL, respectively. However, the calculated CI was found to be >1 in A2780 cells
treated with the melittin + cisplatin combinations at concentrations of 3 + 2 (CI = 2.812) and
4 + 2 (CI = 1.259) µg/mL, and thus could represent an antagonistic effect (Figure 2B). The melittin +
cisplatin combinations had CI between 0.7–0.9, indicating a moderate to slight synergism relationship
in A2780CR at 2 + 10 (CI = 0.888) and 5 + 10 (CI = 0.741) µg/mL, as shown in Figure 3B. The CI value
of melittin + cisplatin was 0.985 at concentrations of 3 + 10 µg/mL and 0.921 at concentrations of
4 + 10 µg/mL used to treat A2780CR, indicating a nearly additive effect. However, the calculated CI
was found >1 in A2780CR with the cisplatin+melittin combination at concentrations of 20 + 2 and
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30 + 2 µg/mL and thus could represent an antagonism effect. The combination of melittin and cisplatin
thus shows potential in the treatment of the resistant cells since there is no evidence of cross resistance
against melittin which might be expected as a feature of multidrug resistance.
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Figure 3. Effect of melittin in combination with cisplatin on (A) cell viability of A2780CR cell lines and
(B) combination index. (A) The A2780CR cells were treated with various concentrations of the melittin
+ cisplatin combination for 24 h. Bar graphs represent mean ± SD values. (B) Combination index
(CI) analysis was generated using the method of Chou and Talalay [21,22] to determine the extent of
synergy, if any, for the melittin + cisplatin combination on A2780CR cell lines.
2.3. Metabolome Analysis
The metabolic effects of melittin in combination with cisplatin on ovarian cancer cells were
assessed using an LC-MS basedmetabolomic approach. Univariate andmultivariate statistical analyses
were used to examine the effect of combination 1 (5 µg/mL of melittin + 2 µg/mL cisplatin) and
combination 2 (2 µg/mL of melittin + 10 µg/mL cisplatin) on A2780 and A2780CR cells, respectively.
A clear separation of A2780 and A2780CR cells was achieved indicating unique metabolite profiles
for the treated and control cells on the PCA and OPLS-DA scores plots at both treatment combinations
(Figure 4A,B, respectively). The pooled quality control (QC) samples injected at intervals in the
analysis run to assess the precision of the measurements and confirm stability of the analytical method
produced a single tight cluster in the center of the dataset (Figure 4A), thus validating the analysis.
The PCA model parameters and validation of the plot suggested a good model (four components,
R2X (cum) = 0.918; Q2 (cum) = 0.856). There was also very clear separations between the treated and
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control A2780 and A2780CR cells in the OPLS-DA, a supervised model for classifying samples. The
OPLS-DA model parameters and validation of the plot suggested a strong model (four components,
R2X (cum) = 0.916, R2Y (cum) = 1, Q2 (cum) = 0.975), and the CV-ANOVA for this model was
1.28 × 10−24. Hierarchical clustering analysis (HCA) of the metabolomics data showed distinct
separation between the control and treated samples (Figure S3).
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Figure 4. (A) Principal components analysis (PCA) vs. (B) Orthogonal Partial Least Squares
Discriminant Analysis (OPLS-DA). PCA and OPLS-DA scores plot generated from PCA and OPLS-DA
using LC-MS normalised data of cells after exposure to the combination (melittin + cisplatin) and
controls of A2780 and A2780CR cell lines. A2780-treated cells at 5 µg/mL melittin + 2 µg/mL cisplatin
(SOS); untreated A2780 cells (C); A2780CR-treated cells at 2 µg/mL melittin + 10 µg/mL cisplatin
(SOR); untreated A2780CR (CR); pooled quality control (QC) samples (P).
There was a very clear separation of the treated versus untreated A2780 cells obtained by using
the OPLS-DA model based on the significant metabolites (Figure 5A). The model parameters and
validation of the plot suggested a strong model (two components, R2X (cum) = 0.965, R2Y (cum) = 1,
Q2 (cum) = 0.996, CV-ANOVA= 2.62 × 10−6). To test the validity, a receiver operator characteristic
(ROC) curve and permutation test were also applied (Figure S3). The area under the curve (AUC)
for the ROC curve is regarded as excellent when AUC > 0.9. The OPLS-DA model classified the
treated and untreated A2780 cells into two groups, and the AUC of the ROC for the groups were in the
excellent to perfect classification.
In the case of the A2780CR cells, OPLS-DA models were also generated by comparing control and
treated samples based on the significant metabolites (Figure 5B). As in A2780 cells, a clear separation
was also found between the treated and untreated A2780CR samples and the CV-ANOVA for this
model was 8.42 × 10−6 (two components, R2X (cum) = 0.966, R2Y (cum) = 1, Q2 (cum) = 0.994).
Furthermore, the validity of the ROC and permutation test showed that the constructed OPLS-DA
model was valid (Figures S4 and S5).
For univariate statistical analysis of candidate specific biomarkers in ovarian cancer cells after
exposure to the treatment combinations, the false discovery rate statistical test (FDR) was used to
reduce the probability of false positive results [23]. Significant changes in the levels of various classes
of metabolites, especially those in the mitochondrial TCA cycle, energy metabolism, and nucleotide
and amino acids metabolism were observed as summarised in Table 1. The major impression is that
the combination of melittin and cisplatin produces distinct metabolic profiles in both cell lines that are
unlike those produced when either of the agents are used alone as previously reported [15,24].
Metabolites 2017, 7, 14 7 of 18
ΐ ΐ
ΐ ΐ
ƺ
 
Figure 5. OPLS-DA score plot of (A) A2780 cells and (B) A2780CR before and after treatment with
melittin + cisplatin respectively. Separation of the treated and untreated cells in both cell lines in the
model suggests that there are significant metabolite differences induced by treatment in both cell lines.
The metabolites responsible for the observed separation are shown in Table 1.
Table 1. Metabolites significantly altered by treatment with melittin in combination with cisplatin
at 5 µg/mL melittin + 2 µg/mL cisplatin on A2780 and at 2 µg/mL melittin + 10 µg/mL cisplatin
on A2780CR.
m/z RT (min) Metabolites
SR/CR SS/C
p-Value Ratio p-Value Ratio
Citrate cycle (TCA cycle)/glycolysis
338.989 18.1 * D-Fructose 1,6-bisphosphate <0.001 0.278 <0.001 0.246
115.004 16.0 * Fumarate <0.001 0.227 <0.01 0.402
133.014 16.1 * (S)-Malate <0.001 0.218 <0.001 0.062
145.014 15.7 * 2-Oxoglutarate <0.001 0.324 <0.001 0.048
191.02 18.1 * Citrate <0.001 0.588 <0.001 0.172
173.009 17.9 * cis-Aconitate <0.001 0.490 <0.001 0.072
166.975 17.5 * Phosphoenolpyruvate <0.001 0.344 <0.05 0.082
Oxidative phosphorylation
664.116 14.2 * NAD+ <0.001 0.294 <0.001 0.067
508.003 16.2 * ATP <0.001 0.362 <0.001 0.073
Glycine/Serine/Cysteine and Glutathione
241.031 16.3 * L-Cystine ns 1.739 ns 1.832
427.095 17.1 S-Glutathionyl-L-cysteine ns 0.750 <0.001 0.218
152.002 14.6 3-Sulfino-L-alanine ns 0.706 <0.001 0.139
308.091 14.5 * Glutathione (GSH) <0.001 0.562 <0.001 0.092
179.048 14.4 L- Cysteinylglycine (Cys-Gly) <0.001 0.521 <0.001 0.067
223.074 17.1 * L-Cystathionine <0.001 0.438 <0.001 0.004
76.0394 15.7 * Glycine ns 1.050 <0.001 0.142
116.035 10.8 L-2-Amino-3-oxobutanoic acid <0.001 0.319 <0.001 0.317
106.050 15.8 * L-Serine <0.001 7.112 <0.001 0.420
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Table 1. Cont.
m/z RT (min) Metabolites
SR/CR SS/C
p-Value Ratio p-Value Ratio
Pentose phosphate pathway
195.051 13.7 * D-Gluconic acid <0.001 0.147 <0.001 0.093
308.978 16.5 D-Ribose 1,5-bisphosphate <0.001 0.259 <0.001 0.124
149.046 11.9 * D-Ribose <0.001 0.222 <0.001 0.285
229.012 15.8 * D-Ribose 5-phosphate <0.001 0.545 <0.001 0.131
Lysine biosynthesis
170.046 14.3 2,3,4,5-Tetrahydrodipicolinate <0.001 0.245 <0.001 0.112
147.113 24.3 * L-Lysine <0.001 1.966 ns 0.724
162.112 13.3 * L-Carnitine <0.001 0.508 <0.001 0.135
243.074 17.2 5-Phosphonooxy-L-lysine <0.001 0.303 <0.001 0.006
128.071 15.5 2,3,4,5-Tetrahydropyridine-2-carboxylate <0.001 0.433 <0.001 0.271
Purine metabolism
137.046 10.2 * Hypoxanthine <0.001 16.99 <0.01 7.87
152.056 12.4 * Guanine <0.001 13.19 <0.01 102.21
348.07 13.8 * AMP <0.001 0.372 <0.001 0.190
428.036 15.0 * ADP <0.001 0.376 <0.001 0.163
442.018 17.8 GDP <0.001 0.509 ns 0.104
521.984 18.9 * GTP <0.001 0.442 <0.001 0.079
426.013 16.9 Adenylyl sulfate <0.001 0.271 <0.01 0.014
Pyrimidine metabolism
155.01 10.3 * Orotate <0.001 0.218 <0.001 0.050
129.066 14.8 5,6-Dihydrothymine <0.001 0.326 <0.001 0.120
480.982 15.8 dTTP <0.001 0.337 <0.001 0.347
175.036 16.8 N-Carbamoyl-L-aspartate <0.001 0.036 <0.001 0.017
115.05 14.7 5,6-Dihydrouracil <0.001 0.383 <0.001 0.079
402.995 16.4 * UDP <0.001 0.485 <0.001 0.035
484.975 17.6 * UTP <0.001 0.465 <0.001 0.059
323.029 15.2 * UMP ns 1.195 <0.001 0.282
Arginine/Proline/Glutamate/Methionine
188.057 14.3 N-Acetyl-L-glutamate <0.001 0.241 <0.001 0.029
176.103 15.8 * L-Citrulline <0.001 0.521 <0.001 0.189
173.104 25.8 * L-Arginine ns 1.161 <0.001 0.379
130.051 14.5 L-Glutamate-5-semialdehyde <0.001 0.538 <0.001 0.235
116.071 12.8 * L-Proline <0.001 0.568 <0.001 0.228
399.144 16.3 * S-Adenosyl-L-methionine <0.001 2.005 <0.001 0.115
298.096 6.4 * 5′-Methylthioadenosine <0.05 2.016 <0.001 0.158
146.093 15.1 * 4-Guanidinobutanoate <0.001 0.325 <0.001 0.055
291.129 16.8 N-(L-Arginino) succinate <0.001 0.260 <0.001 0.010
247.14 14.2 N2-(D-1-Carboxyethyl)-L-arginine <0.001 0.170 <0.001 0.010
174.087 15.3 5-Guanidino-2 oxopentanoate <0.001 0.680 <0.001 0.058
132.077 14.7 * Creatine <0.001 0.403 <0.001 0.075
210.029 15.2 * Phosphocreatine <0.001 0.422 <0.001 0.051
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Table 1. Cont.
m/z RT (min) Metabolites
SR/CR SS/C
p-Value Ratio p-Value Ratio
Miscellaneous
110.027 14.9 Hypotaurine <0.001 0.139 <0.001 0.009
115.04 8.2 3-Methyl-2-oxobutanoic acid <0.001 0.191 <0.05 5.604
166.053 13.4 L-Methionine S-oxide <0.01 0.470 <0.001 0.250
218.067 13.9 O-Succinyl-L-homoserine <0.001 0.082 <0.001 0.011
181.051 9.0 3-(4-Hydroxyphenyl)lactate <0.001 0.656 <0.001 0.087
204.123 11.1 * O-Acetylcarnitine <0.001 0.137 <0.001 0.021
176.056 10.3 4-Hydroxy-4-methylglutamate ns 1.911 <0.001 0.022
159.076 15.8 4-Methylene-L-glutamine <0.001 0.607 ns 0.258
175.025 14.4 * Ascorbate <0.001 0.067 <0.001 0.024
165.041 13.0 L-Arabinonate <0.001 0.372 <0.001 0.166
179.056 17.1 Hexose <0.05 0.670 <0.05 0.334
RT: min; SR: combination 2 treated A2780CR; CR: control A2780CR; SS: combination 1 treated A2780; C: control
A2780; ns: non-significant. * Retention time matches standard.
3. Discussion
Cisplatin is one of the most effective anticancer drugs currently used for treating many types
of cancer, however, it comes with serious side effects. Combination therapy has been used in cancer
treatment in order to increase therapeutic response and tolerability, and to decrease resistance [2].
The present study aimed to determine whether or not melittin, a cytotoxic peptide from bee
venom, possesses a synergistic inhibitory effect in combination with cisplatin on A2780 and A2780CR
cells. In addition, the study was intended to determine the metabolomics effects of the melittin +
cisplatin combination treatment on the two cell lines which would corroborate any observed synergistic
cytotoxic effects.
Cell viability assays using the Alamar® Blue method confirmed the synergistic cytotoxic effects
of melittin in combination with cisplatin at certain concentrations, although at other concentrations,
antagonistic effects were observed. CI analysis of the cytotoxicity data showed that, on A2780 cells,
the combinations had synergistic effects at 2 µg/mL of melittin plus either 5 or 6 µg/mL of cisplatin,
respectively. In contrast, at melittin + cisplatin concentrations of 3 + 2 and 4 + 2 µg/mL, respectively,
antagonistic effects were observed. Synergistic effects were observed in A2780CR cells when the
melittin was combined with cisplatin at 2 + 10 and 5 + 10 µg/mL, while with a fixed concentration of
melittin (2 µg/mL) and variable concentrations of cisplatin (20 and 30 µg/mL) in the combination,
antagonist effects were observed. The CI analysis used the median effect equation of Chou and the
combination index equation of Chou and Talalay to quantify synergism or antagonism at different
concentrations, and to select the best pair of drugs to combine for potentially maximal antitumor
efficacy [22,25]. This method of analysis has been useful in identifying effective combinations of
anticancer drugs [26,27].
Recent studies have reported that components of bee venom may exert an anti-tumour effect
on human ovarian cancer and that the venom has the potential for enhancing the cytotoxic effect of
the antitumor agent cisplatin [14]. Different melittin + cisplatin mechanisms could interact to either
reduce or increase anticancer efficacy, thus producing three possible effects: (1) Additive, when the
combined effect is equal to the sum of individual effects; (2) Antagonistic, when the effect of one or both
compounds is less than when they are applied together than when individually applied; (3) synergism,
when the effect of combined substances is greater than the sum of the individual effects [24]. Our
findings show that these effects can occur depending on the concentrations of melittin and cisplatin in
the combination.
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With respect to OCCs, several previous studies have analysed the metabolic responses of OCCs to
various compounds [28–30]. Additionally, there have been some previous metabolomic studies on
the comparison between the effects of cisplatin on squamous cancer cell lines sensitive and resistant
to cisplatin [31], and the effects of docetaxel on ovarian cancer stem cells [30]. Our previous study
employed a metabolomics approach to assess the effects of melittin monotherapy on OCCs that
revealed significant changes in amino acid and carbohydrate metabolism [15]. In addition, clear
differences were previously observed in the metabolomes of the untreated cells [15]. Although our
study demonstrated profoundmetabolic changes in the cells after melittin monotherapy, there has been
no metabolomics study to date that has comparatively profiled the metabolite composition of OCCs
treated with a combination of melittin and cisplatin. A previous study suggested that combination
therapy is more effective than monotherapy on cancer cells such as hepatocellular carcinoma [19].
In the current untargeted metabolomics study, metabolic profiles of A2780 and A2780CR cells treated
with melittin + cisplatin combinations were assessed using a LC-MS based metabolomics approach,
with OPLS-DA models displaying good separation between the experimental groups, high-quality
goodness of fit (R2), and high-quality goodness of prediction (Q2).
The metabolomics analysis demonstrated distinct metabolic profiles for the treated A2780 and
A2780CR cells, although the treatments were adjusted in accordance with cell sensitivities. Specifically,
the concentrations of melittin and cisplatin usedwere chosen based on cytotoxicity assays and CI values
for synergy to allow detection of a combination effect rather than to achieve a maximal anticancer
effect. The most altered metabolites in A2780 and A2780CR cells could be categorised under amino
acid, energy, carbohydrate, and nucleotide metabolism. Most of the altered metabolites participate
in more than one pathway in significant ways, and the change in that one metabolite could have a
resonating effect for other pathways.
There was a very clear effect of the combination treatment on the purine and pyrimidine pathways.
This was very different from the metabolic shifts observed for melittin and cisplatin alone [15,24],
suggesting the combination has quite a different effect on cell metabolism. There was a very large
increase in the levels of the adenine metabolite, hypoxanthine, and guanine in both cell lines. This
possibly indicates that the combination of melittin with cisplatin is promoting greater adduct formation
between cisplatin and DNA in comparison with the treatment with cisplatin alone, where there was no
strong evidence for effects on the levels of DNA bases [24]. Adducts formed with cisplatin are mainly
intra-strand crosslinks joining two guanine residues and to a lesser extent intra-strand links between
guanine and adenine [32]. DNA is repaired by excision of damaged bases and this would correlate
with largely increased levels of guanine and hypoxanthine, although this presumes that the cisplatin
adduct somehow breaks down during the excision. The levels of the purine metabolites adenosine
monophosphate (AMP), adenosine diphosphate (ADP), and guanosine triphosphate (GTP) were
decreased in both cell lines by the combination treatment. In a previous study, it was found that FK866,
a small molecule inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), caused significant
metabolic changes in purine metabolism in ovarian cancer and colorectal cancer cells [30]. Moreover,
Zhou et al. described a study in hepatocellular carcinoma (HepG2 cells) that showed that high-dose
treatment with sorafenib, an oral multikinase inhibitor, affects purine metabolism with significant
decreases in GTP levels [33]. Despite the profound dose-dependent metabolic changes in HepG2 cells
induced by sorafenib monotherapy, Zhou et al. showed that everolimus, another anticancer agent,
in combination with first-line sorafenib therapy results in more pronounced metabolic changes to
pyruvate, amino acid, methane, glyoxylate, and dicarboxylate, and glycolysis or gluconeogenesis
in hepatocellular carcinoma cells [33]. Other than purine metabolite changes, consistent variations
were observed for pyrimidine metabolism. The levels of pyrimidine metabolites such as orotate,
dihydrothymine, dihydrouracil, and uridine triphosphate (UTP) were reduced in both cell lines after
exposure to the melittin + cisplatin combinations. The reason for the decrease in pyrimidine metabolites
is not clear. Normally DNA damage might be associated with increased levels of dihydrothymine
which is produced by excision of damaged thymine residues from DNA.
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There were many altered metabolites belonging to several pathways for amino acid metabolism.
Most of the metabolites grouped under the arginine and proline pathways were reduced in sensitive
cells after the combination treatments; while the arginine metabolite was non-significantly altered
in resistant cells. Similarly, our previous study examined the effect of melittin on A2780 and
A2780CR cells which showed that the level of arginine was downregulated in cisplatin sensitive
cells compared with resistant cells [15]. A number of studies have reported that arginine deficiency
enhances apoptosis in different cell lines including human lymphoblastic cell lines [34], mesothelioma
cells [35], and melanoma cell lines [36]. Some human cancers, such as melanoma and hepatocellular
carcinoma [37], do not express arginosuccinase synthase and therefore are unable to synthesise arginine
from citrulline [38]. A recent study observed that ovarian carcinoma SKOV3 cells under arginine
deprivation showed increased sensitivity to treatment with paclitaxel, a chemotherapy drug used
to treat cancers, at low doses. In this context, it is to be noted that paclitaxel is a disruptor of the
cytoskeleton and negatively impacts on the autophagosome-lysosome fusion step [39]. A previous
study suggested that combinational treatment based on arginine deprivation and an autophagy
inhibitor (for example chloroquine, a known nontoxic antimalarial drug) can potentially be applied as
a second line treatment for a subset of ovarian carcinomas deficient in argininosuccinate synthetase [39].
It was also observed that the development of chemoresistance to platinum compounds in ovarian
carcinomas leads to collateral appearance of arginine auxotrophy due to the downregulation of
argininosuccinate synthetase [40]. The exact mechanism whereby deficiency arginine biosynthesis
confers resistance remains unclear.
There was a strong effect of the combination treatment on cellular cysteine and glutathione
metabolism; S-glutathionyl-L-cysteine, 3-sulfino-L-alanine, glutathione, L-cysteinylglycine, and
L-cystathionine were all lower in cisplatin sensitive cells compared with resistant cells after being
treated with the combinations. In a previous study, it was found that the level of glutathione was higher
in resistant cells (A2780-CP20) than in sensitive cells (A2780) [41]. This finding resembles the current
results in which the level of glutathione was higher in resistant cells than sensitive cells following
combination treatment. Two of the main reasons for platinum resistance in OCCs are the p53 mutation
and drug-induced increases in intracellular glutathione concentration. A study byMohell et al. showed
that methylene quinuclidinone (MQ), in addition to binding to cysteine residues in p53, also binds
to glutathione, decreasing intracellular glutathione levels in OCCs [42]. Therefore, it is possible that
the combination promotes greater binding of cisplatin to glutathione thus depleting its levels which
occurs to a greater extent in the sensitive cells. Mohell et al. also observed that combination effects of
APR-246 (which is a prodrug that is converted to the active compound MQ) with doxorubicin were the
cause of a DNA damage response, including activation of the p53 pathway leading to apoptosis [42].
Moreover, recent metabolomics based studies in OCCs have demonstrated that gossypol decreases
cellular levels of GSH and induces apoptosis through oxidative stress [30]. In our previous study it was
observed that the levels of GSHwere no different between resistant and sensitive cells. However, in the
current study GSH is depleted by the combination treatment to a much greater extent in the sensitive
cells. The depletion appears to be related to the ability of the cells to synthesise GSH. Although
there is no difference between the cysteine levels in the two cell lines, there are marked differences in
key intermediates which can be used to synthesise both cysteine and GSH including glycine, serine,
cystathionine, and glutathione cysteine. There are also lower levels of S-adenosylmethionine in the
treated sensitive cells which is a source of homocysteine which is also a precursor of cysteine.
Increased serine biosynthesis is one of many metabolic changes that have been reported in cancer
cells [43,44], and serine is a central node for the biosynthesis of many molecules such as glycine
and cysteine [45]. High levels of serine in cancer cells have been linked to increased rates of cell
proliferation [46]. The level of serine was increased in resistant cells following the combination
treatment. In contrast, treatment of the sensitive cells with the combination resulted in a decrease
of serine within the cells and a further lowering of the nonessential amino acid glycine. Glycine is
incorporated directly into purine nucleotide bases and into GSH. The conversion of serine to glycine,
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catalysed by serine hydroxymethyltransferase (SHMT), donates a one-carbon unit to tetrahydrofolate
to produce 5, 10-methylenetetrahydrofolate (CH2-THF). CH2-THF is used in thymidine synthesis
and is a precursor of other folate species that contribute to purine synthesis [46]. The difference
in OCCs could be reflected at the cellular level in terms of differences in the metabolite profiles.
Serine is required for a number of biosynthetic and signalling pathways, including the production of
phospholipids such as sphingolipids and phosphatidylserine [46]. Previous studies have shown that
serine biosynthesis appears to be part of an adaptive response to oxidative stress [47]. The tumour
suppressor p53 is emerging as an important regulator of cellular metabolism. P53 is a key player in the
cellular response to stress in the form of numerous challenges, including DNA damage, hypoxia, and
oncogene activation [48]. Cells lacking p53 fail to respond to serine starvation due to oxidative stress,
which leads to reduced viability and severely impaired proliferation [49].
The level of ATP was found to be reduced in both cell lines after the combination treatment. ATP
was found to be more reduced in both cell lines when treated with the combinations compared with
the results observed previously with melittin monotherapy [15]. It is known that glycolysis provides
ATP and energy in most cell types, but cancer cells extensively use glycolysis to sustain anabolism,
which is necessary for tumour growth [50]. We found that the combinations inhibited glycolysis in
both cell lines as indicated by lower levels of fructose bisphosphate and phosphopyruvate. In addition,
several TCA cycle intermediates were lowered. Cell death can be executed by different mechanisms,
including apoptosis, autophagy, necrosis, or combinations of these processes. Although different cell
death mechanisms are unique in their molecular signalling cascades, one molecule is involved in the
processes that mediates all types of cell death; ATP. During late-stage apoptosis, ATP levels sharply
drop, mostly because of the loss of mitochondrial function and consumption by ATP-dependent
proteases. In autophagy, a rescue process of self-degradation to compensate for energy paucity occurs,
that also features ATP insufficiency prior to cell death [50,51]. During necrosis, depletion of ATP
precedes mitochondrial permeability changes [52]. The fact that ATP deprivation occurs in all types of
cell death suggests that energy metabolism may play a critical role in the survival of cancer cells under
stress. Thus, it could be possible that the A2780 cells may be undergoing late-stage apoptosis cell
death in response to the combination treatment whereas the A2780CR may be undergoing early-stage
apoptosis cell death. In our study, we found that combination treatment probably inhibited glycolysis
in A2780 cells by depletion of NAD+. Moreover, the level of NAD+ was found to be decreased in
A2780CR cells after combination treatment. It appears that the combinations had more impact on
the oxidative phosphorylation pathway in both cell lines in comparison with melittin as a single
treatment [15]. The inhibition of NAMPT leads to suppression of tumour cell growth and induction
of apoptosis due to NAD+ depletion [53]. NAMPT represents a promising therapeutic target for
the development of potential novel cancer drugs [54,55]. In most cancer cells, poly (ADP-ribose)
polymerase is activated due to DNA damage and cell death induced by oxidative stress [56,57].
Therefore, NAMPT inhibition leads to attenuation of glycolysis, resulting in further alteration of the
carbohydrate metabolism in the cells [53].
4. Materials and Methods
4.1. Cell Lines and Cultures
The cisplatin-sensitive (A2780) and resistant (A2780CR) human ovarian carcinoma cells were
obtained from ECACC (Porton Down, Salisbury, UK) and maintained at 75 × 104 cells/mL in RPMI
1640 medium (Lonza, Verviers, Belgium) supplemented with 1% (v/v) L-glutamine (Invitrogen, Paisley,
UK), 100 IU/mL/100 µg/mL penicillin/streptomycin (Invitrogen, Paisley, UK), and 10% (v/v) foetal
bovine serum (FBS) (Life Technologies, Carlsbad, CA, USA). In addition, the cultures for the A2780CR
cells contained 3 µg/mL of cisplatinum (Tocris Bioscience, Bristol, UK) in the first three passages.
Sub-confluent cultures were split by trypsinisation every 4–5 days and maintained at 37 ◦C in a
humidified atmosphere saturated with 5% CO2.
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4.2. Cell Viability Assay
Cisplatin was purchased from Tocris Bioscience (Bristol, UK) and was dissolved in sterile water
with gentle warming according to the manufacturer’s instructions. Melittin was purified from bee
venom (supplied by Beesen Co. Ltd., Dae Jeon, Korea) by reversed phase liquid chromatography [58]
and reconstituted in sterile water to form a stock solution of 1 mg/mL before storage at −20 ◦C
until required. Cell viability was assessed by an Alamar® Blue cell assay (Thermo Fisher Scientific,
Loughborough, UK), as previously described [15].
To test the synergistic cytotoxic effect, experiments were performed with A2780 and A2780CR
cell lines using various combinations of melittin with cisplatin in medium, to assess possible
synergistic/additive effects. Both A2780 and A2780CR cells were seeded at 1× 104 cells/well in 96-well
plates (Corning®, Sigma-Aldrich, Poole, UK) and incubated at 37 ◦C and 5% CO2 in a humidified
atmosphere for 24 h. For the A2780 cell line, 3, 4, 5, and 6 µg/mL of melittin was combined with
2 µg/mL of cisplatin and 3, 4, and 5 µg/mL of cisplatin was combined with 3 µg/mL of melittin.
For the A2780CR cell line, 2, 3, 4 and 5 µg/mL of melittin was combined with 10 µg/mL of cisplatin
and 20 and 30 µg/mL of cisplatin was combined with 2 µg/mL of melittin. Twenty hours after drug
treatment, AB was added at a final concentration of 10% (v/v) and the resultant mixture was incubated
for a further 4 h at 37 ◦C and 5% CO2. Then, the plates were read at an excitation wavelength of 560 nm
and the emission at 590 nm was recorded on a SpectraMax M3 microplate reader (Molecular Devices,
Sunnyvale, CA, USA). All experiments were performed in triplicate.
4.3. Calculation of CI
The specific interaction between melittin and cisplatin on A2780 and A2780CR cancer cell lines
was evaluated by the CI analysis. Drug combination synergy was performed using CompuSyn
software [59]. CI values and CI-Fa plot (plot representing CI versus Fa, the fraction affected by
a particular dose) were calculated by CompuSyn program (Compusyn Inc., Paramus, NJ, USA).
All experiments were repeated at least three times.
4.4. Statistical Analysis
GraphPad Prism for Windows (version 5.00, GraphPad Software, San Diego, CA, USA) was
employed to produce dose-response curves by performing nonlinear regression analysis of the cell
viability data. The mean IC50 values were calculated from at least three measurements of independent
experiments (n = 3).
4.5. Determination of the Effect of Melittin in Combination with Cisplatin on Cell Metabolomes
The A2780 cell line was treated with the combination of melittin and cisplatin at concentrations of
5 and 2 µg/mL, respectively, for 24 h (n = 5). The A2780CR cells were treated with the combination
of melittin and cisplatin at concentrations of 2 and 10 µg/mL, respectively, for 24 h (n = 5). The cells
were seeded at 75 × 104 cells/mL in T-25 cell culture flasks and incubated for 1 doubling time (48 h)
before treatment with the combinations and incubation for an additional 24 h. After the treatment, the
medium was removed and the cells were washed twice with 3 mL of phosphate-buffered saline (PBS)
at 37 ◦C before lysis. Cell lysates were prepared by extraction with ice cold methanol:acetonitrile:water
(50:30:20) (1 mL per 2 × 106 cells). The cells were scraped and cell lysates mixed on a Thermo mixer
at 1440 rotations per minute (r.p.m.) for 12 min at 4 ◦C, before being centrifuged at 13500 r.p.m. for
15 min at 0 ◦C. The supernatants were collected and transferred into HPLC vials for LC-MS analysis.
During the analysis, the temperature of the autosampler was maintained at 4 ◦C. Mixtures of standard
metabolites (Sigma-Aldrich, Poole, UK) and the pooled quality control (QC) sample were injected in
each analysis run in order to facilitate identification and to evaluate the stability and reproducibility
of the analytical method. The pooled QC sample was obtained by taking equal aliquots from all the
samples and placing them into the same HPLC vial.
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4.6. LC-MS Conditions
Liquid chromatographic separation was carried out on an Accela HPLC system interfaced to an
Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) using a hydrophilic
interaction liquid chromatography (HILIC) column (ZIC-pHILIC, 150 × 4.6 mm, 5 µm particle size)
supplied by Hichrom Ltd. (Reading, UK). The method was reported previously [60]. Briefly, the mobile
phase for ZIC-pHILIC consisted of 20 mM ammonium carbonate (Sigma-Aldrich, Poole, UK) in water
purified by Direct-Q3 Ultrapure water purification system (Millipore, UK) at pH 9.2 (solvent A) and
acetonitrile (Sigma-Aldrich, Poole, UK) (solvent B) at a flow rate of 0.3 mL/min. The elution gradient
was an A:B ratio of 20:80 at 0 min, 80:20 at 30 min, 92:8 at 35 min, and finally 20:80 at 45 min.
4.7. Data Extraction and Analysis
Data extraction for each of the samples was carried out by MZmine-2.10 software
(mzmine.github.io/) using identical parameters for peak detection, deconvolution, deisotoping,
alignment, filtering, and gap filling in order to make multiple data files comparable [23]. The extracted
ions, with their corresponding m/z values and retention times, were pasted into an Excel macro of
the most common metabolites prepared in–house to facilitate identification, and a library search was
also carried out against accurate mass data of the metabolites in the Human Metabolome, Kyoto
Encyclopedia of Genes and Genomes, and Metlin databases. The lists of the metabolites obtained
from these searches were then carefully evaluated manually by considering the quality of their peaks
and their retention time match to the standard metabolite mixtures run in the same sequence. The
MS data were log2-transformed and mean-centred with unit variance scaling for statistical analysis.
Statistical analyses were performed using both univariate and multivariate approaches. The p-values
from univariate analysis were adjusted using the FDR control and differences in the levels (or peak
areas) of the metabolites between treated and control cells were considered significant at p < 0.05.
MetaboAnalyst®, a web-based metabolomic data processing tool [60], was used for supporting
fold-change analysis, and t-tests. SIMCA-P software version 14.0 (Umetrics, Crewe, UK) was also
used for multivariate analysis of the metabolite data with Pareto scaling prior to modelling with PCA
and OPLS-DA. OPLS-DA models were validated based on multiple correlation coefficient (R2) and
cross-validated R2 (Q2) in cross-validation and permutation tests.
5. Conclusions
Based on the results presented, a metabolic signature for the cisplatin and melittin combination
treatment for A2780 and A2780CR OCCs is proposed. Melittin and cisplatin together have different
metabolic effects on these cells compared to melittin alone, which preferentially affects fatty acids,
amino acids, and TCA cycle intermediates. The most significantly affected metabolites due to
the melittin + cisplatin combination treatment in both cell lines were in the TCA cycle, oxidative
phosphorylation, purine and pyrimidine metabolism, and arginine/proline pathways. This distinct
mechanism of action of the melittin + cisplatin combination may provide a new paradigm for
overcoming chemoresistance in ovarian cancer therapy. Our results provide rationale for the ongoing
study of melittin in combination with cisplatin that could produce improved therapy for platinum
resistance in ovarian cancer.
Supplementary Materials: The following are available online at www.mdpi.com/2218-1989/7/2/14/s1,
Figure S1: Cell viability was determined following treatment with cisplatin for 24 h (A) IC50 = 10.8 µg/mL
A2780CR; (B) IC50 = 4.9 µg/mL A2780, Figure S2: Cell viability was determined following treatment with melittin
for 24 h (IC50 = 6.8 µg/mL A2780; IC50 = 4.5 µg/mL A2780CR), Figure S3: Hierarchical clustering analysis (HCA)
of 20 ovarian cancer cell samples. It shows two main groups and four subgroups. The groups: CR, control
of cisplatin resistance cell lines; SOR: A2780CR after treatment with melittin + cisplatin; C, control of cisplatin
sensitive cell lines; SOS, A2780 after treatment with melittin + cisplatin, Figure S4: (A) Permutation analysis of
OPLS-DA model derived from A2780 cells treated with melittin/cisplatin and controls cells. Statistical validation
of the OPLS-DA model by permutation analysis using 100 different model permutations. The goodness of fit
(R2) and predictive capability (Q2) of the original model are indicated on the far right and remain higher than
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those of the 100 permuted models to the left. OPLS-DA, orthogonal partial least squares discriminant analysis.
(B) Receiver Operating Characteristics (ROC) curve shows sensitivity (true positive rate (TPR)) on the y-axis
versus (false positive rate (FPR = 1 - Specificity)) on the x-axis. The area under ROC curve (AUROCC) = 1 for SOS
and C groups, Figure S5: (A) Permutation analysis of OPLS-DA model derived from A2780CR cells treated with
melittin/cisplatin and controls cells. Statistical validation of the OPLS-DA model by permutation analysis using
100 different model permutations. The goodness of fit (R2) and predictive capability (Q2) of the original model
are indicated on the far right and remain higher than those of the 100 permuted models to the left. OPLS-DA,
orthogonal partial least squares discriminant analysis. (B) Receiver Operating Characteristics (ROC) curve shows
sensitivity (true positive rate (TPR)) on the y-axis versus (false positive rate (FPR = 1 - Specificity)) on the x-axis.
The area under ROC curve (AUROCC) = 1 for SOR and CR groups.
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